CG Oncology(CGON) - 2025 Q1 - Quarterly Results

Corporate Highlights Exhibit 99.1 | CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M - - Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M - - New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive blad ...